Evommune, Inc. (EVMN NYSE) stock market data APIs
$19.9647
0.62(3.1%)
as of June 12, 2026
Try our APIs with
free plan!
Evommune, Inc. Financial Data Overview
Price chart is built with
Anychart
Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products include EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is based in Palo Alto, California.
Prev. Close
19.9647
Open
20.5875
High
21.4899
Low
19.8054
52 wk Range
13.885-33.2
Market Cap
714 M
Shares Outstanding
36 018 K
Revenue
10 000 K
EPS
-0.6437
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Evommune, Inc. (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Evommune, Inc. data using free add-ons & libraries
Get Evommune, Inc. Fundamental Data
Evommune, Inc. Fundamental data includes:
- Net Revenue: 10 000 K
- EBITDA: -88 632 000
- Earnings Per Share: -2
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-05-08
- EPS/Forecast: -0.8475
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Evommune, Inc. News
New
Nan Fung Group Sells $4.3 Million in Oculis Shares As Lead Drug Stumbles
What happened According to a recent SEC filing, Nan Fung Group Holdings Ltd reduced its position in Oculis(NASDAQ:OCS) by 163,957 shares during the first quarter of 2026. The estimated value of the t...
Nan Fung Group Sells $4.3 Million in Oculis Shares As Lead Drug Stumbles
Key Points Nan Fung Group Holdings sold 163,957 Oculis (OCS) shares in Q1 2026, with an estimated transaction value of $4.3 million. After the sale, Nan Fung's remaining stake of 350,745 shares was v...
Trevi Therapeutics Is Up 100%, Pivotal bioVenture Adds Anyway. Here's Why That Matters.
Pivotal bioVenture Partners Investment Advisor increased its position in Trevi Therapeutics(NASDAQ:TRVI) during the first quarter, acquiring 296,944 shares in an estimated $3.32 million trade based on...
Velan Capital Drops 140,000 Mineralys Therapeutics (MLYS) Shares Worth $4.1 Million
Key Points Reduced stake by 140,000 shares; estimated transaction value of $4.11 million based on quarterly average price Quarter-end position value fell by $5.18 million, reflecting both trading and...
Get Evommune, Inc. fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
